188 related articles for article (PubMed ID: 20482871)
21. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
22. High level of Sema3C is associated with glioma malignancy.
Vaitkienė P; Skiriutė D; Steponaitis G; Skauminas K; Tamašauskas A; Kazlauskas A
Diagn Pathol; 2015 Jun; 10():58. PubMed ID: 26032848
[TBL] [Abstract][Full Text] [Related]
23. Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.
Koo T; Lim DH; Seol HJ; Dho YS; Kim IH; Chang JH; Lee J; Jung TY; Gwak HS; Cho KH; Hong CK; Lee IJ; Kim E; Kim JH; Hong YK; Jang HS; Kim CY; Kim IA; Kim SH; Kim YI; Kim EY; Kim WC; Hong S
J Neurooncol; 2018 Nov; 140(2):445-455. PubMed ID: 30097825
[TBL] [Abstract][Full Text] [Related]
24. Diet and risk of adult glioma in eastern Nebraska, United States.
Chen H; Ward MH; Tucker KL; Graubard BI; McComb RD; Potischman NA; Weisenburger DD; Heineman EF
Cancer Causes Control; 2002 Sep; 13(7):647-55. PubMed ID: 12296512
[TBL] [Abstract][Full Text] [Related]
25. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
26. Survival and low-grade glioma: the emergence of genetic information.
Claus EB; Walsh KM; Wiencke JK; Molinaro AM; Wiemels JL; Schildkraut JM; Bondy ML; Berger M; Jenkins R; Wrensch M
Neurosurg Focus; 2015 Jan; 38(1):E6. PubMed ID: 25552286
[TBL] [Abstract][Full Text] [Related]
27. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma.
Lan F; Qing Q; Pan Q; Hu M; Yu H; Yue X
Cell Oncol (Dordr); 2018 Feb; 41(1):25-33. PubMed ID: 29076027
[TBL] [Abstract][Full Text] [Related]
28. Up-Regulation of Long Non-Coding RNA AB073614 Predicts a Poor Prognosis in Patients with Glioma.
Hu L; Lv QL; Chen SH; Sun B; Qu Q; Cheng L; Guo Y; Zhou HH; Fan L
Int J Environ Res Public Health; 2016 Apr; 13(4):433. PubMed ID: 27104549
[TBL] [Abstract][Full Text] [Related]
29. [Survival of newly diagnosed malignant glioma patients on combined modality therapy].
Yang QY; Shen D; Sai K; Jiang XB; Ke C; Zhang XH; Mou YG; Chen ZP
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(1):8-10. PubMed ID: 23578444
[TBL] [Abstract][Full Text] [Related]
30. FGF2 as a potential prognostic biomarker for proneural glioma patients.
Sooman L; Freyhult E; Jaiswal A; Navani S; Edqvist PH; Pontén F; Tchougounova E; Smits A; Elsir T; Gullbo J; Lennartsson J; Bergqvist M; Ekman S
Acta Oncol; 2015 Mar; 54(3):385-94. PubMed ID: 25263081
[TBL] [Abstract][Full Text] [Related]
31. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
[TBL] [Abstract][Full Text] [Related]
32. High miR-196a and low miR-367 cooperatively correlate with unfavorable prognosis of high-grade glioma.
Guan Y; Chen L; Bao Y; Qiu B; Pang C; Cui R; Wang Y
Int J Clin Exp Pathol; 2015; 8(6):6576-88. PubMed ID: 26261539
[TBL] [Abstract][Full Text] [Related]
33. Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945.
Eisenstat DD; Pollack IF; Demers A; Sapp MV; Lambert P; Weisfeld-Adams JD; Burger PC; Gilles F; Davis RL; Packer R; Boyett JM; Finlay JL
J Neurooncol; 2015 Feb; 121(3):573-81. PubMed ID: 25431150
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma.
Liu H; Liu B; Hou X; Pang B; Guo P; Jiang W; Ding Q; Zhang R; Xin T; Guo H; Xu S; Pang Q
J Neurooncol; 2017 May; 132(3):409-417. PubMed ID: 28321704
[TBL] [Abstract][Full Text] [Related]
35. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001.
Claus EB; Black PM
Cancer; 2006 Mar; 106(6):1358-63. PubMed ID: 16470608
[TBL] [Abstract][Full Text] [Related]
36. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients.
Lote K; Egeland T; Hager B; Stenwig B; Skullerud K; Berg-Johnsen J; Storm-Mathisen I; Hirschberg H
J Clin Oncol; 1997 Sep; 15(9):3129-40. PubMed ID: 9294476
[TBL] [Abstract][Full Text] [Related]
37. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
[TBL] [Abstract][Full Text] [Related]
38. Low expression of miR-1231 in patients with glioma and its prognostic significance.
Wang H; Wu J; Luo WJ; Hu JL
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8399-8405. PubMed ID: 30556881
[TBL] [Abstract][Full Text] [Related]
39. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma.
Wu W; Lamborn KR; Buckner JC; Novotny PJ; Chang SM; O'Fallon JR; Jaeckle KA; Prados MD
Neuro Oncol; 2010 Feb; 12(2):164-72. PubMed ID: 20150383
[TBL] [Abstract][Full Text] [Related]
40. Long-term prognostic assessment of 185 newly diagnosed gliomas: Grade III glioma showed prognosis comparable to that of Grade II glioma.
Shinohara C; Muragaki Y; Maruyama T; Shimizu S; Tanaka M; Kubota Y; Oikawa M; Nakamura R; Iseki H; Kubo O; Takakura K; Hori T
Jpn J Clin Oncol; 2008 Nov; 38(11):730-3. PubMed ID: 18820008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
